Healthcare - Biotechnology - NASDAQ - US
$ 4.95
-13.6 %
$ 95.6 M
Market Cap
-4.27
P/E
CASH FLOW STATEMENT
-16 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
15.1 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nuvectis Pharma, Inc.
| Net Income | -22.3 M |
| Depreciation & Amortization | -1 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 4.7 M |
| Change in Working Capital | 1.6 M |
| Others | 1.74 M |
| Free Cash Flow | -16 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (22.3) | (19.1) | (12.9) | 24 K |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 4.7 | 1.7 | 1.9 | 0 |
| Other Operating Activities | 0 | (2.4) | 0.3 | 24 K |
| Change in Working Capital | 1.6 | 3.8 | 1.5 | 10 K |
| Cash From Operations | (16.0) | (13.6) | (9.5) | 24 K |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | 0 | 0 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 0 | 0 | 0 |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.8 | (4.1) | 15.2 | 0 |
| Cash From Financing Activities | 15.1 | 27.8 | 15.2 | 0 |
| CHANGE IN CASH | ||||
| Net Change In Cash | (0.9) | 14.3 | 5.7 | 24 K |
| FREE CASH FLOW | ||||
| Free Cash Flow | (16.0) | (13.6) | (9.5) | 24 K |